Technology
Smartphone app shown to improve memory recall

A new smartphone app, designed by University of Toronto researchers, has been shown to significantly improve memory recall in older adults.
In a study published in the Proceedings of the National Academy of Sciences, University of Toronto (U of T) researchers have demonstrated that their new smartphone application helps to significantly improve memory recall, which could prove beneficial for individuals in the early stages of Alzheimer’s disease or other forms of memory impairment.
Known as HippoCamera for its ability to mimic the function of the brain’s hippocampus in memory construction and retention, the app enhances the encoding of memories stored in the brain by boosting attention to daily events and consolidating them more distinctly, thus later enabling richer, more comprehensive recall.
In a two-step process, HippoCamera users record a short video of up to 24 seconds of a moment they want to remember with a brief eight-second audio description of the event. The app combines the two elements just as the brain’s hippocampus would, with the video component sped up to mimic aspects of hippocampal function and to facilitate efficient review. Users then replay cues produced by HippoCamera at later times on a curated and regular basis to reinforce the memory and enable detailed recall.
“We found that memories with an associated HippoCamera cue were long-lasting, and that it worked for everyone in the study – healthy older adults, those starting to show cognitive decline, and even one case with severe amnesia due to an acquired brain injury,” said study co-author and professor Morgan Barense, Canada Research Chair in Cognitive Neuroscience in the Department of Psychology in the Faculty of Arts & Science at U of T who is leading the development of the app.
“Many months after the initial part of the study ended, and participants had not watched their HippoCamera cues, they were able to recall these memories in rich detail.”
The study shows that regular users of the app were able to recall over 50 per cent more details about everyday experiences that took place as many as six months earlier, than if they had only recorded events and never replayed them.
The new research suggests that systematic reactivation of memories for recent real-world experiences can help to maintain a bridge between the present and past in older adults and holds promise for people in the early stages of Alzheimer’s disease or other forms of memory impairment.
The study also found that reviewing memory cues with HippoCamera resulted in more positive sentiment during later retrieval.
“So, there’s something about being better able to remember these events that made people feel closer to them and more positive,” said Professor Barense, who is also an adjunct scientist at the Rotman Research Institute at Baycrest.
“This is a really important finding given what we know about dementia and the fact that positive reminiscence or focusing on positive life events and positive emotions can improve both memory and well-being in dementia.”
For the study, participants recorded unique HippoCamera clips for everyday events that they wanted to remember and subsequently replayed these memory cues approximately eight times over a two-week period in one experiment, and over a ten-week period in a second experiment. The researchers then initiated a cued recall task, where they showed the participants their memory cues and asked them to describe everything they could remember about each event.
This was followed by fMRI brain scanning sessions where researchers measured patterns of brain activity while participants saw their cues and completed a memory test. Three months later, after not practicing their HippoCamera memories and not having access to the cues, the participants were asked to recall these events a second time.
“On average, we saw on later recall an increase of more than 50 per cent in the amount of rich, detailed information that someone was able to remember, about events that happened as many as 200 days ago, which is significant,” said Chris Martin, an assistant professor in the Department of Psychology at Florida State University and lead author of the study.
“Memory is truly self-sustaining – a strong memory cue can bring along another memory, which can feed into another. You just have to focus on the cue in the first place.”
Further, the brain scans showed that replaying HippoCamera memory cues changed the way in which these everyday experiences were coded in the hippocampus, which has a well-established role in storing detailed memories for recent experiences.
Recall-related activity in the hippocampus was more distinctive, meaning that HippoCamera replay helps to ensure that memories for different events remain separate from one another in the brain.
“The more detailed recollection seen earlier in the study was associated with more differentiated memory signals in the hippocampus,” said Martin.
“That HippoCamera is aiding the hippocampus in distinctly encoding memories, so they do not become confused with one another, explains why users are able to recall past events in such great detail. It’s evidence that rich and detailed memory reactivation promotes memory differentiation at the neural level, and that this allows us to mentally re-experience the past with vivid detail.”
One key factor in HippoCamera’s effectiveness, the researchers say, is the sense of purpose and intention inherent in its use. By its very design, the intervention prompts users to think about what it is that they want to remember and why a particular moment is important to them, and then regularly re-engage with the memories in a meaningful way.
“Someone who is committed to using HippoCamera is going to go through their lives paying attention to what is happening to them, asking themselves if this is an event they want to capture,” said Professor Barense.
“If it is, they’re going to take the time to stop and describe that event. And that act of approaching events in our lives with more attention is going to be good for memory.
“Then later, there’s an intention with how we study those memories, taking the time to review them using optimal learning techniques.”
The researchers note that as people begin to lose their existing memories at any point in their lives, as well as their ability to create new ones, they start to lose their sense of self. As a result, they often become disengaged from the people and events in their lives.
“Memory and our sense of identity are very closely linked,” said Professor Barense, who is receiving support from U of T startup accelerator UTEST to take the app from lab to market.
“We understand who we are as people by remembering the things that we’ve done. Our hope with HippoCamera is that by helping people feel closer to these people and events in their lives, we can help give them back their sense of self.”
News
PrimeC shows survival benefit in ALS trial

PrimeC showed a more than 14-month survival benefit in an ALS trial, according to updated long-term data from NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd announced updated long-term survival data from its completed Phase 2b PARADIGM clinical trial of its investigational therapy PrimeC in patients with amyotrophic lateral sclerosis (ALS), according to the company.
The analysis showed that patients who received PrimeC continuously during both the double-blind and open-label phases achieved an estimated median survival of 36.3 months, compared with 21.4 months for those initially assigned to placebo, representing a more than 14-month improvement in survival.
After adjusting for baseline risk factors, a statistical model indicated that PrimeC treatment was associated with a 65 per cent reduction in the risk of death compared with placebo, reinforcing the magnitude of the observed survival advantage, the company said.
The PARADIGM trial evaluated PrimeC, an investigational extended-release oral formulation combining two existing FDA-approved drugs, in 68 patients with ALS.
The updated survival results build on previously reported evidence of slowed disease progression and a favourable safety and tolerability profile seen in the same study.
NeuroSense stated that these survival findings provide additional clinical context to support advancement of PrimeC into pivotal late-stage development and strengthen its engagement with regulatory authorities.
The therapy remains investigational and has not been approved for marketing.
Technology
AI predicts walking recovery after hip surgery

An AI model using gait data before and after hip replacement could help predict which patients will walk close to normal and who may need extra rehabilitation.
The tool analyses gait biomechanics, the study of how people walk, using data collected before and after operations in people with hip osteoarthritis, caused by cartilage wear in the hip joint.
The study examined 109 patients with unilateral hip osteoarthritis before total hip replacement. Of these, 63 were reassessed after surgery, while 56 healthy people acted as a control group.
The analysis, developed by researchers at Karlsruhe Institute of Technology and Universitätsmedizin Frankfurt, identified three patient groups with different patterns of change in how they walked.
Some improved markedly and walked almost normally after surgery, while others still showed clear deviations from the control group.
Three-dimensional joint angle and joint loading data were gathered through musculoskeletal modelling. Certain measurements, including hip angles and joint loads, were especially useful in assigning patients to the right group. The groups also differed in age, height, weight, walking speed and osteoarthritis severity.
Dr Bernd J. Stetter, who leads a musculoskeletal health and technology research group at Karlsruhe Institute of Technology, said: “Our model makes it possible to predict who will benefit especially well from an operation and who will need additional intensive therapy afterwards.
“Since the algorithms are explainable and transparent, we expect the model to enjoy a high level of clinical acceptance.”
The researchers said the model could help clinicians make better-informed decisions, set more realistic expectations with patients and tailor rehabilitation after surgery.
While the model was trained for artificial hip joints, the team said the approach could potentially be adapted to other joints and conditions.
Around 200,000 people in Germany received artificial hip joints in 2024, making it one of the country’s most common orthopaedic procedures.
News
First blood test for Alzheimer’s in primary care

Labcorp has launched what it describes as the first FDA-cleared blood test for Alzheimer’s disease assessment in primary care settings nationwide.
The Elecsys pTau-181 helps clinicians rule out the neurodegenerative disorder by identifying which symptomatic patients aged 55 and older are unlikely to have amyloid pathology, abnormal protein build-up in the brain associated with the disease.
Patients with negative results can be evaluated for other potential causes of cognitive decline, while patients with positive results can be referred for additional testing.
The diagnostic was developed by Roche Diagnostics and cleared by the US Food and Drug Administration in 2025.
Brian Caveney, chief medical and scientific officer at Labcorp, said: “Primary care clinicians are often the first point of contact for patients with concerns related to cognitive symptoms, yet Alzheimer’s testing has historically required a visit to a specialist.
“By making this first-of-its-kind blood test available nationwide, Labcorp is giving primary care clinicians a powerful tool to help patients get answers sooner and guide next steps with confidence.”
The Elecsys pTau-181 offers 97.9 per cent negative predictive value, a measure of how accurately it can rule out the condition in symptomatic patients, according to the company.
The diagnostic is performed via a simple blood draw, which can be completed in a doctor’s office or at any of Labcorp’s more than 2,200 patient service centres nationwide.
It provides an alternative to traditional approaches that require brain scans or lumbar punctures, procedures to collect spinal fluid, which can be costly, invasive or difficult to access.
The company says it can help reduce unnecessary referrals amid a national shortage of neurologists, supporting timely evaluation of other causes of cognitive decline.
An estimated 7.2 million Americans live with the disease.
Labcorp’s portfolio includes blood-based biomarker diagnostics for Alzheimer’s disease and other forms of dementia.
News4 weeks agoNanoparticles target disease proteins in dementia
News4 weeks agoL-Nutra raises US$36.5m in series D funding
Insights3 weeks agoInterview: Dr Annu Navani on biotechnology and ‘the power to recode life itself’
News4 weeks agoGap partners with Spear Bio on Bio-Hermes-002
Insights3 weeks agoDentordu: Digital dentistry for healthier ageing
News4 weeks agoBioAge expands drug into diabetic macular oedema
News3 weeks agoStudy shows clear link between CTE and dementia risk
News4 weeks agoUSC funds AI projects for Alzheimer’s trials



















